RARE vs REPL · rev $560.2M vs $825.7M cap
Ultragenyx (RARE) versus Replimune Group Inc (REPL) — a side-by-side from cached financials, not a winner call.
Ultragenyx (RARE) is a biotechnology company listed on US.
Replimune Group Inc (REPL) is a biotechnology company listed on NASDAQ.
Latest reported RARE revenue for 2024-12-31 was $560.2M. Net income was -$569.2M. Revenue was up 29.0% from 2023-12-31 to 2024-12-31. RARE currently screens at market cap $2.79B.
REPL does not have a complete income-statement cache yet.
RARE currently screens at market cap $2.79B. REPL currently screens at market cap $825.7M.
Not investment advice. Open the RARE and REPL stock pages for the full models.
Not investment advice.